Report: Orphan Drug Appears to Slow ALS Progression

Masitinib, a drug that’s already received “Orphan Drug Designation” from the U.S. Food & Drug Administration (FDA), appeared to slow the progression of amyotrophic lateral sclerosis (ALS) in early results of a double-blind, phase 2/3 controlled trial, Medscape reported on April 7.

The drug’s manufacturer, AB Science, specializes in developing tyrosine kinase inhibitors that it hopes will be able to treat cancers, chronic inflammatory diseases and neurological degenerative disorders.

Masitinib has been available in the United States to treat cancerous tumors in dogs since 2010. The FDA grants Orphan Drug Designations to drugs developed to treat, diagnose or prevent rare diseases. In some cases, the drugs’ manufacturers are not expected to recover the costs of developing and producing the medications due to the relatively low number of patients who will use it.

About the Author

Laurie Watanabe is the editor of Mobility Management. She can be reached at lwatanabe@1105media.com.

Upcoming Webcast

CRT Funding: Updates & Expectations for Interesting Times

Join long-time reimbursement specialist Jim Stephenson of Permobil on December 13 as we recap 2018 and discuss what to expect in CRT funding and payor policies for 2019.

Accessibility Technology Comparo

Subscribe to eMobility

Mobility Management's free email newsletter keeping you up-to-date and informed.

I agree to this site's Privacy Policy